In the 30 years that biomedical researchers have worked determinedly to find a cure for Alzheimer’s disease, their counterparts have developed drugs that helped cut deaths from cardiovascular disease by more than half, and cancer drugs able to eliminate tumors that had been incurable. But for Alzheimer’s, not only is there no cure, there is not even a disease-slowing treatment.

The brain, Alzheimer’s researchers patiently explain, is hard — harder than the heart, harder even than cancer. While that may be true, it is increasingly apparent that there is another, more disturbing reason for the tragic lack of progress: The most influential researchers have long believed so dogmatically in one theory of Alzheimer’s that they systematically thwarted alternative approaches. Several scientists described those who controlled the Alzheimer’s agenda as “a cabal.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Thanks Sharon for a timely article and thanks for interviewing me. But the biggest problem with addressing “Alzheimer’s” is not that amyloid has become a pharmaceutical target of exaggerated importance, but that pharmaceutical approaches are themselves viewed as the best way to prevent dementia and improve quality of life of people today and in the future. So-called Alzheimers is not one condition and dementia is related to aging. Public health, educational, and arts approaches embedded in community will continue to better address our social and ecological challenges, not only having to do with dementia but in general. Neoliberal politics have created vast social and economic inequities that contribute to social determinants of poor brain and general health. We need to not only recognize that we have poorly thought through, bad ideas about the role of amyloid in the brain but worst conceptions of Alzheimer’s in our minds and societies.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy